Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation

被引:11
作者
Yamazaki, Osamu [1 ]
Ubara, Yoshifumi [1 ]
Suwabe, Tatsuya [1 ]
Nakanishi, Shohei [1 ]
Hoshino, Junichi [1 ]
Sawa, Naoki [1 ]
Hayami, Noriko [1 ]
Yamanouchi, Masayuki [1 ]
Takemoto, Fumi [1 ]
Kenmei, Takaichi [1 ]
Masuoka, Kazuhiro [2 ]
Oohashi, Kenichi [3 ]
机构
[1] Toranomon Gen Hosp, Nephrol Ctr, Takatsu Ku, Kanagawa 2120015, Japan
[2] Toranomon Gen Hosp, Dept Hematol, Kawasaki Ku, Kanagawa, Japan
[3] Toranomon Gen Hosp, Dept Pathol, Kawasaki Ku, Kanagawa, Japan
关键词
AL amyloidosis; Autologous peripheral blood stem cell transplantation; SCT; High-dose melphalan; Proteinuria; VAD; (vincristine; doxorubicin; and dexamethasone); NEPHROTIC SYNDROME; SURVIVAL; SUPPORT;
D O I
10.1007/s10157-009-0198-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We report a 58-year-old Japanese man with primary systemic AL amyloidosis who achieved disappearance of proteinuria including Bence-Jones protein (lambda-type) after two courses of VAD therapy (vincristine, doxorubicin, and dexamethasone) and subsequent high-dose melphalan, followed by autologous peripheral blood stem cell transplantation. Because this patient did not have any apparent amyloidosis-related heart or liver damage and met all of the eligibility criteria for this therapy, this treatment was performed. Both proteinuria and M-protein disappeared completely, and he is doing well clinically at 19 months after treatment. However, amyloid deposits were still found in the kidneys, including the glomeruli and tubulointerstitium, when renal biopsy was done at 8 months after treatment. In the future, we may reach a time when clinical remission corresponds to histological remission.
引用
收藏
页码:522 / 525
页数:4
相关论文
共 9 条
  • [1] Autologous stem cell transplantation for primary systemic amyloidosis
    Comenzo, RL
    Gertz, MA
    [J]. BLOOD, 2002, 99 (12) : 4276 - 4282
  • [2] Comenzo RL, 1998, BLOOD, V91, P3662
  • [3] VAD with or without subsequent melphalan followed by autologous high-dose stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection
    Gono, T
    Matsuda, M
    Shimojima, Y
    Ishii, W
    Koyama, J
    Sakashita, K
    Koike, K
    Hoshii, Y
    Ikeda, S
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2004, 11 (04): : 245 - 256
  • [4] Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation
    Gono, T
    Matsuda, M
    Dohi, N
    Hoshi, K
    Tada, T
    Sakashita, K
    Koike, K
    Aizawa, M
    Ikeda, S
    [J]. INTERNAL MEDICINE, 2003, 42 (01) : 72 - 77
  • [5] High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Jaccard, Arnaud
    Moreau, Philippe
    Leblond, Veronique
    Leleu, Xavier
    Benboubker, Lotfi
    Hermine, Olivier
    Recher, Christian
    Asli, Bouchra
    Lioure, Bruno
    Royer, Bruno
    Jardin, Fabrice
    Bridoux, Frank
    Grosbois, Bernard
    Jaubert, Jerome
    Piette, Jean-Charles
    Ronco, Pierre
    Quet, Fabrice
    Cogne, Michel
    Fermand, Jean-Paul
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (11) : 1083 - 1093
  • [6] A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
    Kyle, RA
    Gertz, MA
    Greipp, PR
    Witzig, TE
    Lust, JA
    Lacy, MQ
    Therneau, TM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (17) : 1202 - 1207
  • [7] KYLE RA, 1995, SEMIN HEMATOL, V32, P45
  • [8] Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients
    Moreau, P
    Leblond, V
    Bourquelot, P
    Facon, T
    Huynh, A
    Caillot, D
    Hermine, O
    Attal, M
    Hamidou, M
    Nedellec, G
    Ferrant, A
    Audhuy, B
    Bataille, R
    Milpied, N
    Harousseau, JL
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (04) : 766 - 769
  • [9] The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone
    Wardley, AM
    Jayson, GC
    Goldsmith, DJA
    Venning, MC
    Ackrill, P
    Scarffe, JH
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (06) : 774 - 776